CINECA IRIS Institutional Research Information System

MARMORINO, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.824
AS - Asia 2.388
EU - Europa 1.638
SA - Sud America 387
AF - Africa 141
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.386
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.721
SG - Singapore 870
IT - Italia 681
CN - Cina 526
HK - Hong Kong 390
BR - Brasile 304
VN - Vietnam 234
DE - Germania 177
GB - Regno Unito 145
SE - Svezia 145
FR - Francia 117
BG - Bulgaria 93
FI - Finlandia 57
CA - Canada 55
IN - India 54
JP - Giappone 54
CI - Costa d'Avorio 53
NL - Olanda 48
RU - Federazione Russa 48
TR - Turchia 36
BD - Bangladesh 35
ID - Indonesia 35
KR - Corea 32
AR - Argentina 30
AT - Austria 30
PL - Polonia 30
MX - Messico 26
IQ - Iraq 19
NG - Nigeria 19
SN - Senegal 16
ZA - Sudafrica 15
ES - Italia 13
UA - Ucraina 13
VE - Venezuela 13
SA - Arabia Saudita 11
PK - Pakistan 10
UZ - Uzbekistan 10
CL - Cile 9
PH - Filippine 8
AE - Emirati Arabi Uniti 7
CO - Colombia 7
EC - Ecuador 7
MA - Marocco 7
CH - Svizzera 6
PE - Perù 6
CZ - Repubblica Ceca 5
IL - Israele 5
JM - Giamaica 5
OM - Oman 5
PT - Portogallo 5
PY - Paraguay 5
TN - Tunisia 5
UY - Uruguay 5
BE - Belgio 4
JO - Giordania 4
LB - Libano 4
LT - Lituania 4
NZ - Nuova Zelanda 4
PA - Panama 4
PS - Palestinian Territory 4
TH - Thailandia 4
AL - Albania 3
AO - Angola 3
AU - Australia 3
CR - Costa Rica 3
DZ - Algeria 3
EG - Egitto 3
ET - Etiopia 3
KE - Kenya 3
KH - Cambogia 3
KZ - Kazakistan 3
NP - Nepal 3
QA - Qatar 3
TT - Trinidad e Tobago 3
BF - Burkina Faso 2
CY - Cipro 2
EE - Estonia 2
HR - Croazia 2
IE - Irlanda 2
KG - Kirghizistan 2
LY - Libia 2
MY - Malesia 2
NI - Nicaragua 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TG - Togo 2
TM - Turkmenistan 2
TW - Taiwan 2
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GH - Ghana 1
Totale 8.373
Salva come PNG Salva come JPEG
Città #
Singapore 484
Ashburn 450
Hong Kong 382
Woodbridge 294
Santa Clara 293
Fairfield 286
San Jose 261
Dallas 224
Chandler 196
Shanghai 138
Seattle 125
Houston 111
New York 110
Ann Arbor 108
Cambridge 102
Wilmington 100
Sofia 93
Pisa 76
Boardman 75
Beijing 73
Los Angeles 73
Ho Chi Minh City 72
Florence 69
Milan 68
London 67
Abidjan 53
Hefei 52
Munich 52
Princeton 47
Tokyo 47
Lauterbourg 46
Lawrence 44
Hanoi 39
Medford 38
Seoul 32
Council Bluffs 31
Rome 31
Serra 31
São Paulo 29
Warsaw 29
Genoa 28
Ottawa 26
Bremen 25
Redondo Beach 25
Frankfurt am Main 24
Dearborn 23
Helsinki 23
Turku 23
Buffalo 22
Istanbul 22
Des Moines 21
Turin 20
Vienna 20
Lagos 19
Ogden 18
Seacroft 18
Cascina 17
Dakar 16
Naples 16
Düsseldorf 15
Lancaster 15
Orem 15
San Diego 14
Da Nang 12
Phoenix 12
Fuzhou 11
Jakarta 11
Nanjing 11
Boulder 10
Dong Ket 10
Nuremberg 10
Baghdad 9
Chicago 9
Dhaka 9
Montreal 9
Denver 8
Johannesburg 8
Redwood City 8
San Francisco 8
Tashkent 8
Toronto 8
Bandung 7
Bari 7
Gargallo 7
Hyderabad 7
Mumbai 7
Rio de Janeiro 7
Atlanta 6
Carrara 6
Curitiba 6
Haiphong 6
Lucca 6
Marseille 6
Quanzhou 6
Biên Hòa 5
Boston 5
Brasília 5
Chennai 5
Hangzhou 5
Kent 5
Totale 5.681
Salva come PNG Salva come JPEG
Nome #
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 215
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 214
Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients 197
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 191
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 188
TAS-102 for the treatment of metastatic colorectal cancer 181
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 178
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 175
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 175
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 173
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 168
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 168
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 168
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 167
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 166
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 164
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 158
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 158
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 157
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 152
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 150
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 147
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 143
Surgery combined with intra-operative microwaves ablation for the management of colorectal cancer liver metastasis: A case-matched analysis and evaluation of recurrences 143
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 142
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 141
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 140
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 139
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials 136
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis 134
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 133
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 132
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 131
Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial 130
null 129
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 129
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 128
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 123
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 122
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 121
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO 118
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei 117
Immune checkpoint inhibitors in pmmr metastatic colorectal cancer: A tough challenge 117
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 112
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 112
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 111
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 108
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 104
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 103
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 99
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 99
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial 97
Fast, Direct Dihydrouracil Quantitation in Human Saliva: Method Development, Validation, and Application 96
null 91
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib 90
Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon 81
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome 74
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 70
Acyl-CoA binding protein for the experimental treatment of anorexia 65
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers 64
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer 63
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 60
KDR genetic predictor of toxicities induced by sorafenib and regorafenib 55
Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer 51
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 50
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 49
Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm 37
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials 27
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients 27
null 15
Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement Study 9
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 7
The Impact of Surgical Resection in Early Onset Colorectal Cancer Patients With Liver Limited Disease 3
Totale 8.587
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.393
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.393
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202186 0 0 0 0 0 0 0 0 0 0 24 62
2021/2022427 10 11 10 11 65 64 7 19 28 42 35 125
2022/2023763 69 115 45 55 73 90 18 45 148 5 86 14
2023/2024716 49 61 105 65 75 107 66 28 20 27 58 55
2024/20252.236 76 70 69 108 204 231 173 108 197 267 229 504
2025/20262.765 216 309 295 318 325 202 379 179 195 256 91 0
Totale 8.587